Progress in the study of PEG-IFNα therapy in reducing HBV-related hepatocellular carcinoma
ZHENG Ying-ying
ZENG Da-wu
Abstract：Hepatocellular carcinoma(HCC)remains a malignant tumor that severely affects the health of the people in our country.The most common cause of HCC in our country is infection with the hepatitis B virus(HBV).Although eliminating HBV remains a challenge,antiviral therapy can indeed induce the reversal of liver fibrosis and reduce the incidence of HCC.For patients undergoing antiviral therapy,the risk of liver cancer is reduced by 40％-60％compared to patients who have not received treatment.Currently,anti-HBV drugs aredivided into pegylated interferon(PEG-IFNα)and nucleos(t)ide analogs(NAs).Even under active anti-HBV treatment,the risk of HCC still exists.Existing evidence suggests that PEG-IFNα is superior to NAs in reducing HBV-related HCC,and this article reviews the research progress in PEG-IFNαin reducing HBV-related HCC.
Keywords：hepatitis B viruspegylated interferon alphahepatocellular carcinoma
Publication Date：2025-02-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 105-109 )